Arteriosclerosis is an indication for drug development with over 120 pipeline drugs currently active. According to GlobalData, preregistered drugs for Arteriosclerosis have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Arteriosclerosis compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Arteriosclerosis overview
Arteriosclerosis refers to the thickening and hardening of arteries due to plaque buildup, limiting blood flow. Atherosclerosis, a common form, involves cholesterol and other substances accumulating in arterial walls, narrowing them. This condition heightens the risk of heart disease, stroke, and peripheral artery disease. Factors like high blood pressure, cholesterol, smoking, diabetes, and obesity contribute. Management involves lifestyle changes—such as a healthy diet and exercise—and medications to control risk factors. Sometimes, procedures like angioplasty or stent placement help restore blood flow. Preventive measures and early management play pivotal roles in reducing complications associated with arteriosclerosis.
For a complete picture of PTSR and LoA scores for drugs in Arteriosclerosis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
